Trial · NCT02611765
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
NCT02611765, Phase 4, Completed, Baylor College of Medicine; results first posted 2016-04-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study. Trials, record NCT02611765. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02611765
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
- NCT number
- NCT02611765
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 64 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Syphilis
- Interventions
- Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units
- First posted
- 2015-11-23
- Last updated
- 2016-05-17
- Results first posted
- 2016-04-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) | 12 months | Number of participants who achieve treatment success. Loss to follow-up was assumed to be a failure. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) | 12 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) | Enhanced Therapy | 27 | participants | ||
| Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) | Standard Therapy | 28 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Enhanced Therapy | 29 | |
| Overall Study | STARTED | Standard Therapy | 35 | |
| Overall Study | COMPLETED | Enhanced Therapy | 27 | |
| Overall Study | COMPLETED | Standard Therapy | 29 | |
| Overall Study | NOT COMPLETED | Enhanced Therapy | 2 | |
| Overall Study | NOT COMPLETED | Standard Therapy | 6 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Enhanced Therapy | ||
| Total, all-cause mortality | Standard Therapy | ||
| Total, other adverse events | Enhanced Therapy | 0 | 29 |
| Total, other adverse events | Standard Therapy | 0 | 35 |
| Total, serious adverse events | Enhanced Therapy | 0 | 29 |
| Total, serious adverse events | Standard Therapy | 0 | 35 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28200045 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Enhanced Therapy vs Standard Therapy: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) | Trial comparisons |
| Enhanced Therapy vs Standard Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02611765
GET https://conductscience.org/api/trials/v1/NCT02611765/registered